Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations.

JAMA Netw Open · 2020 · PMC7593810 · PMID 33112397

Europe PMC DOI

hedged sentence

0.2000

closest p · 4.0× alpha

0.2000

boldest claim

The sentences

did not reach statistical significanceP = .20not close (p > 0.1)

Median (IQR) OS from start of platinum-based therapy was lower in patients without DNA repair gene aberrations compared with patients with known DNA repair gene aberrations (9.2 [5.5-19.5] months vs 14.1 [5.7-33.7] months), although this did not reach statistical significance ( P = .20) ( Figure 3 ; Table 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.